Get the Stockscreener App
13.34
1.06%
0.14
Pre-market:
13.34
Eyepoint Inc stock is traded at $13.34, with a volume of 905.00K.
It is up +1.06% in the last 24 hours and up +2.46% over the past month.
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.
See More
Previous Close:
$13.20
Open:
$13.29
24h Volume:
905.00K
Relative Volume:
0.71
Market Cap:
$1.12B
Revenue:
$31.37M
Net Income/Loss:
$-231.96M
P/E Ratio:
-4.2172
EPS:
-3.1632
Net Cash Flow:
$-243.39M
1W Performance:
-3.12%
1M Performance:
+2.46%
6M Performance:
+1.91%
1Y Performance:
+87.10%
1-Day Range:
$12.98
$13.74
1-Week Range:
$12.53
$14.30
52-Week Range:
$5.30
$19.11
Eyepoint Inc Stock (EYPT) Company Profile
Name
Eyepoint Inc
Sector
Industry
Phone
617-926-5000
Address
480 PLEASANT STREET, WATERTOWN, MA
Compare EYPT vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EYPT
Eyepoint Inc
|
13.34 | 1.12B | 31.37M | -231.96M | -243.39M | -3.1632 |
VRTX
Vertex Pharmaceuticals Inc
|
423.92 | 107.83B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
701.42 | 73.54B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
783.50 | 48.72B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
296.11 | 39.51B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
293.86 | 32.66B | 5.36B | 287.73M | 924.18M | 2.5229 |
Eyepoint Inc Stock (EYPT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-17-25 | Initiated | RBC Capital Mkts | Outperform |
| Jan-07-25 | Initiated | Citigroup | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Aug-28-24 | Initiated | Jefferies | Buy |
| Jan-22-24 | Initiated | JP Morgan | Overweight |
| Nov-02-23 | Initiated | Mizuho | Buy |
| Apr-21-23 | Initiated | Robert W. Baird | Outperform |
| Jul-07-22 | Initiated | Chardan Capital Markets | Buy |
| Mar-01-21 | Initiated | Cowen | Outperform |
| Jan-28-21 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-06-20 | Downgrade | B. Riley FBR | Buy → Neutral |
| Nov-04-19 | Resumed | Laidlaw | Buy |
| Sep-12-19 | Initiated | Guggenheim | Buy |
View All
Eyepoint Inc Stock (EYPT) Latest News
MSN Money - MSN
Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Given Consensus Rating of "Buy" by Analysts - MarketBeat
Earnings Preview: EyePoint to Report Financial Results Pre-market on May 06 - Moomoo
Is EyePoint (NASDAQ:EYPT) In A Good Position To Invest In Growth? - Moomoo
Eyepoint Pharmaceuticals (EYPT) to Release Quarterly Earnings on Wednesday - MarketBeat
EyePoint to Report First Quarter 2026 Financial Results on May 6, 2026 - Yahoo Finance
EyePoint (NASDAQ: EYPT) plans virtual 2026 meeting and larger equity pool - Stock Titan
EyePoint, Inc. Income Statement – NASDAQ:EYPT - TradingView
EYPT (EyePoint Inc.) shares rise 2.02 percent despite wider Q4 2025 loss and 27.5 percent year over year revenue drop.Shared Momentum Picks - Cổng thông tin điện tử tỉnh Lào Cai
Top Executive Makes Strategic Move With EyePoint Pharmaceuticals Stock - TipRanks
Understanding Momentum Shifts in (EYPT) - Stock Traders Daily
EyePoint CMO Ramiro Ribeiro sells $36,555 in company shares By Investing.com - Investing.com South Africa
EyePoint CMO Ramiro Ribeiro sells $36,555 in company shares - Investing.com
[Form 4] EyePoint, Inc. Insider Trading Activity - Stock Titan
Is EyePoint (EYPT) stock reversing trend (Bullish Sentiment) 2026-04-20Fast Rising Picks - Cổng thông tin điện tử Tỉnh Sơn La
Enrolment concludes in EyePoint’s Phase III programme of Duravyu for wet AMD - MSN
[144] EyePoint, Inc. SEC Filing - Stock Titan
EyePoint, Inc. (EYPT) Stock Analysis: Unpacking a 150% Potential Upside in the Booming Biotech Sector - DirectorsTalk Interviews
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Sahm
Eyepoint reports inducement grants under Nasdaq listing rule 5635(c)(4) - marketscreener.com
EyePoint hires 14 employees, grants 362,500 stock options - Stock Titan
JPMorgan Chase & Co. Sells 217,150 Shares of Eyepoint Pharmaceuticals, Inc. $EYPT - MarketBeat
EyePoint Highlights DURAVYU Phase 3 Progress and Cash Runway - TipRanks
EyePoint posts April 2026 investor presentation; DURAVYU Phase 3 updates, cash runway into Q4 2027 - TradingView
DURAVYU Phase 3 plans and cash runway outlined by EyePoint (EYPT) - Stock Titan
Will EyePoint (EYPT) Stock Miss Expectations | Price at $14.00, Down 1.34%Social Momentum Signals - Cổng thông tin điện tử tỉnh Tây Ninh
EyePoint Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Avoiding Lag: Real-Time Signals in (EYPT) Movement - Stock Traders Daily
Recap Report: What is the long term forecast for EyePoint Pharmaceuticals Inc stockQuarterly Trade Report & Free Community Consensus Stock Picks - baoquankhu1.vn
Stocks to watch: EyePoint sees relative strength rating rise to 92 - MSN
What are analysts saying about EyePoint (EYPT) Stock | Price at $13.57, Up 3.51%Community Momentum Stocks - Cổng thông tin điện tử Tỉnh Sơn La
Aug Reactions: What are analysts price targets for EyePoint Pharmaceuticals IncPrice Action & Fast Gain Swing Trade Alerts - baoquankhu1.vn
Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Stock Price Down 3.7%Time to Sell? - marketbeat.com
Arvinas (ARVN) moves 6.9% higher: Will this strength last? - MSN
Aberdeen Group plc Has $29.34 Million Position in Eyepoint Pharmaceuticals, Inc. $EYPT - MarketBeat
EyePoint Inc at RBC Capital Markets Ophthalmology Conference (Virtual) Transcript - GuruFocus
Chardan raises EyePoint stock price target to $29 on cash position - Investing.com
EyePoint, Inc. (EYPT) stock price, news, quote and history - Yahoo Finance UK
Parkman Healthcare Partners LLC's EyePoint Inc(EYPT) Holding History - GuruFocus
Earnings call transcript: Eyepoint Pharmaceuticals Q4 2025 reveals revenue drop - Investing.com
Q3 2025 EyePoint Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
STU:PV3B PB Ratio: 3.51 — 21% Below Median - GuruFocus
EYPT PE Ratio & Valuation, Is EYPT Overvalued - Intellectia AI
EyePoint Inc (EYPT) Stock Price Quote Today & Current Price Chart - capital.com
EyePoint Inc : Jefferies Assumes Coverage Wit - Moomoo
Discipline and Rules-Based Execution in EYPT Response - Stock Traders Daily
Stock List: Research Stocks from Around the World - gurufocus.com
Tech Rally: What is the PEG ratio of EyePoint Pharmaceuticals Inc2026 Outlook & Precise Swing Trade Entry Alerts - baoquankhu1.vn
[SCHEDULE 13G/A] EyePoint, Inc. Amended Passive Investment Disclosure - Stock Titan
EyePoint Pharmaceuticals at RBC Conference: Strategic Progress in Ophthalmology By Investing.com - ca.investing.com
Eyepoint Inc Stock (EYPT) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.45%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):